JP2015517463A - 黄色ブドウ球菌感染および関連状態を処置および予防する方法 - Google Patents

黄色ブドウ球菌感染および関連状態を処置および予防する方法 Download PDF

Info

Publication number
JP2015517463A
JP2015517463A JP2015510278A JP2015510278A JP2015517463A JP 2015517463 A JP2015517463 A JP 2015517463A JP 2015510278 A JP2015510278 A JP 2015510278A JP 2015510278 A JP2015510278 A JP 2015510278A JP 2015517463 A JP2015517463 A JP 2015517463A
Authority
JP
Japan
Prior art keywords
cd11b
lukab
aureus
candidate compounds
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015510278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517463A5 (https=
Inventor
ビクター ジェイ． トーレス
ビクター ジェイ． トーレス
アシュレー エル． デュモン
アシュレー エル． デュモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Publication of JP2015517463A publication Critical patent/JP2015517463A/ja
Publication of JP2015517463A5 publication Critical patent/JP2015517463A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
JP2015510278A 2012-05-02 2013-03-15 黄色ブドウ球菌感染および関連状態を処置および予防する方法 Pending JP2015517463A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641543P 2012-05-02 2012-05-02
US61/641,543 2012-05-02
PCT/US2013/032436 WO2013165613A1 (en) 2012-05-02 2013-03-15 Methods of treating and preventing staphylococcus aureus infections and associated conditions

Publications (2)

Publication Number Publication Date
JP2015517463A true JP2015517463A (ja) 2015-06-22
JP2015517463A5 JP2015517463A5 (https=) 2016-04-21

Family

ID=49514732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015510278A Pending JP2015517463A (ja) 2012-05-02 2013-03-15 黄色ブドウ球菌感染および関連状態を処置および予防する方法

Country Status (9)

Country Link
US (1) US9657103B2 (https=)
EP (1) EP2844287A4 (https=)
JP (1) JP2015517463A (https=)
CN (1) CN104428000A (https=)
AU (1) AU2013257161B2 (https=)
CA (1) CA2871152A1 (https=)
HK (1) HK1207981A1 (https=)
IL (1) IL235284A0 (https=)
WO (1) WO2013165613A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160108106A1 (en) * 2013-05-21 2016-04-21 Arsanis Biosciences Gmbh Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
WO2016197071A1 (en) * 2015-06-05 2016-12-08 New York University Compositions and methods for anti-staphylococcal biologic agents
US11685785B2 (en) * 2015-06-12 2023-06-27 Ascendo Biotechnology, Inc. Methods and antibodies for modulation of immunoresponse
EP3638286A4 (en) * 2017-06-13 2021-03-10 Integrated Biotherapeutic Vaccines, Inc. IMMUNOGENIC COMPOSITIONS CONTAINING POLYPEPTIDES DERIVED FROM LEUCOCIDINS LUKA AND LUKB OF STAPHYLOCOCCUS AUREUS
US12291562B2 (en) 2019-04-01 2025-05-06 Rush University Medical Center Reagents and assays using modified integrin domains
CN114437187B (zh) * 2022-02-09 2023-06-20 淮北师范大学 一种细菌素Bacin A4及其应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504827A (ja) * 2000-07-31 2004-02-19 ザ　ジェネラル　ホスピタル　コーポレーション 高親和性インテグリンポリペプチドおよびその使用方法
JP2006508648A (ja) * 2002-08-28 2006-03-16 ユニヴァーシティ オヴ フロリダ 肝幹細胞からの神経新生
JP2006094701A (ja) * 2002-09-17 2006-04-13 Chugai Pharmaceut Co Ltd ７ｆ４遺伝子トランスジェニック動物
JP2007319073A (ja) * 2006-05-31 2007-12-13 Japan Health Science Foundation ユートロフィン遺伝子発現増強物質のスクリーニング
JP2008537478A (ja) * 2005-02-24 2008-09-18 ザ・スクリプス・リサーチ・インステイチユート 単離骨髄球様骨髄細胞集団及びそれを用いた治療方法
JP2008220174A (ja) * 2007-03-08 2008-09-25 Tokyoto Igaku Kenkyu Kiko 変異型βシヌクレインとαシヌクレインとを共発現する形質転換細胞及びトランスジェニック非ヒト動物
WO2011103490A2 (en) * 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
JP2011246495A (ja) * 2004-10-12 2011-12-08 Genentech Inc 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
WO2012005800A1 (en) * 2010-07-08 2012-01-12 Adhaere Pharamaceuticals, Inc. Compounds and methods for regulating integrin cd11b/cd18
JP6031029B2 (ja) * 2010-05-05 2016-11-24 ニューヨーク・ユニバーシティ 黄色ブドウ球菌ロイコシジン、その治療用組成物、および使用
JP6093760B2 (ja) * 2011-06-19 2017-03-08 ニューヨーク・ユニバーシティ 抗炎症剤および殺菌剤としてのロイコトキシンｅ／ｄ

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
US20030162956A1 (en) 1997-04-07 2003-08-28 Human Genome Sciences, Inc. Leukocyte regulatory factors 1 and 2
US7323552B2 (en) 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
WO2006086500A2 (en) 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20100310665A1 (en) * 2007-10-25 2010-12-09 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
MX357938B (es) 2011-06-19 2018-07-31 Univ New York Metodos para tratar y prevenir infecciones por staphylococcus aureus y afecciones asociadas.

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504827A (ja) * 2000-07-31 2004-02-19 ザ　ジェネラル　ホスピタル　コーポレーション 高親和性インテグリンポリペプチドおよびその使用方法
JP2006508648A (ja) * 2002-08-28 2006-03-16 ユニヴァーシティ オヴ フロリダ 肝幹細胞からの神経新生
JP2006094701A (ja) * 2002-09-17 2006-04-13 Chugai Pharmaceut Co Ltd ７ｆ４遺伝子トランスジェニック動物
JP2011246495A (ja) * 2004-10-12 2011-12-08 Genentech Inc 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
JP2008537478A (ja) * 2005-02-24 2008-09-18 ザ・スクリプス・リサーチ・インステイチユート 単離骨髄球様骨髄細胞集団及びそれを用いた治療方法
JP2007319073A (ja) * 2006-05-31 2007-12-13 Japan Health Science Foundation ユートロフィン遺伝子発現増強物質のスクリーニング
JP2008220174A (ja) * 2007-03-08 2008-09-25 Tokyoto Igaku Kenkyu Kiko 変異型βシヌクレインとαシヌクレインとを共発現する形質転換細胞及びトランスジェニック非ヒト動物
WO2011103490A2 (en) * 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
JP6031029B2 (ja) * 2010-05-05 2016-11-24 ニューヨーク・ユニバーシティ 黄色ブドウ球菌ロイコシジン、その治療用組成物、および使用
WO2012005800A1 (en) * 2010-07-08 2012-01-12 Adhaere Pharamaceuticals, Inc. Compounds and methods for regulating integrin cd11b/cd18
JP6093760B2 (ja) * 2011-06-19 2017-03-08 ニューヨーク・ユニバーシティ 抗炎症剤および殺菌剤としてのロイコトキシンｅ／ｄ

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EXP.DERMATOL., vol. 2, JPN6016046247, 1993, pages 171 - 174, ISSN: 0003452512 *
PNAS, vol. 110(26), JPN6016046252, June 2013 (2013-06-01), pages 10794 - 10799, ISSN: 0003452515 *
THE JOURNAL OF IMMUNOLOGY, vol. 157, JPN6016046251, 1996, pages 4133 - 4140, ISSN: 0003452514 *
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 304(3), JPN6016046249, 2003, pages 1016 - 1024, ISSN: 0003452513 *

Also Published As

Publication number Publication date
HK1207981A1 (en) 2016-02-19
US20150132310A1 (en) 2015-05-14
CA2871152A1 (en) 2013-11-07
IL235284A0 (en) 2014-12-31
WO2013165613A1 (en) 2013-11-07
AU2013257161B2 (en) 2017-11-09
EP2844287A1 (en) 2015-03-11
AU2013257161A1 (en) 2014-11-20
EP2844287A4 (en) 2016-01-27
US9657103B2 (en) 2017-05-23
CN104428000A (zh) 2015-03-18

Similar Documents

Publication Publication Date Title
JP7129451B2 (ja) 黄色ブドウ球菌感染および関連状態を治療および予防する方法
JP2015517463A (ja) 黄色ブドウ球菌感染および関連状態を処置および予防する方法
JP2020037595A (ja) Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
AU2016353073A1 (en) Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
Kim Investigating bacterial penetration of the blood–brain barrier for the pathogenesis, prevention, and therapy of bacterial meningitis
JP2019178164A (ja) 黄色ブドウ球菌ロイコシジンの細胞毒性に関与する細胞因子：新規治療標的
AU2013295242C1 (en) CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
Fahnoe et al. Development and optimization of bifunctional fusion proteins to locally modulate complement activation in diseased tissue
EP4212168A1 (en) Novel composition for prevention or treatment of staphylococcus aureus infectious disease
Sproch Elucidating the Mechanism of Host Cell Lysis by S. aureus Leukocidin HlgAB
HK40101755A (zh) 用於预防或治疗金黄色葡萄球菌感染性疾病的新型组合物
de Jong et al. GENERAL INTRODUCTION-Immune evasion by Staphylococcus aureus
HK1190640A (en) Methods of treating and preventing staphylococcus aureus infections and associated conditions
HK1190640B (en) Methods of treating and preventing staphylococcus aureus infections and associated conditions
HK40004629B (en) Pharmaceutical compositions containing a mutated leukocidin e
NZ730359B2 (en) Methods of treating and preventing staphylococcus aureus infections and associated conditions
HK40000719A (en) Methods of treating and preventing staphylococcus aureus infections and associated conditions
HK40000719B (en) Methods of treating and preventing staphylococcus aureus infections and associated conditions

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160229

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180205